TITLE

SAIK-MS Expected to Enter Phase II As Early As Q4, 2000

PUB. DATE
January 2000
SOURCE
Worldwide Biotech;Jan2000, Vol. 12 Issue 1, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Focuses on SAIKS-MS, Active Biotech's substance against multiple sclerosis which is expected to enter Phase II in the fourth quarter of 2000.
ACCESSION #
2685747

 

Related Articles

  • Discontinuation of higher laquinimod doses in two MS trials.  // Reactions Weekly;1/16/2016, Vol. 1584 Issue 1, p1 

    An abstract is presented of the article "Teva and Active Biotech Announce Discontinuation of Higher Doses of Laquinimod in Two Multiple Sclerosis Trials" published on January 4, 2016 on the website www.tevapharm.com.

  • Teva and Active Biotech amend marketing and distribution agreement.  // PharmaWatch: CNS;Mar2010, Vol. 9 Issue 3, p5 

    No abstract available.

  • Teva/Active Biotech: laquinimod clinical program moves on.  // PharmaWatch: CNS;Jul2007, Vol. 6 Issue 7, p5 

    The author reflects on the gap that exists in the orally administered treatments for relapsing multiple sclerosis (MS). He asserts that laquinomoid, an autoimmune suppressant used for treating relapsing MS, is behind from other oral MS treatments in the clinical trial process. He stresses that...

  • Other News To Note.  // BioWorld International;10/26/2011, Vol. 16 Issue 43, p3 

    The article offers news briefs on drug manufacturing. A Phase III trial of laquinimod by Sweden's Active Biotech AB and Jerusalem's Teva Pharmaceutical Industries Ltd. showed that it significantly reduced the relapse of multiple sclerosis. Danish drug manufacturer Affitech received 2.5 million...

  • Teva, Active Down Following Laquinimod Phase III Miss. Wall, Tom // BioWorld Today;8/2/2011, Vol. 22 Issue 148, p1 

    The article reports on the decline in stocks of pharmaceutical companies Active Biotech AB and Teva Pharmaceutical Industries Ltd. It states that the decline came as a result of the announcement that laquinimod, an oral multiple sclerosis drug, failed to decrease the annualized relapse rate in...

  • Teva's MS Drug Nails Primary Endpoints -- and Then Some. Powers, Marie // BioWorld Today;12/10/2010, Vol. 21 Issue 238, p1 

    The article reports on the result of the two-year Phase III ALLEGRO study of the oral laquinimod for relapsing-remitting multiple sclerosis (RRMS) developed by Teva Pharmaceuticals which demonstrated a significant reduction in annualized relapse rate compared to placebo. The drug, which Teva is...

  • Teva/Active Biotech: laquinimod clinical program moves on.  // PharmaWatch: Monthly Review;Jul2007, Vol. 6 Issue 7, p15 

    The article reports on the positive result of the test of laquinimod, an oral disease modifying treatment for multiple sclerosis. Phase III clinical trials are initiated by Teva and Swedish biotech partner Active Biotech AB. It is stated that laquinimod is expected to become the fifth oral...

  • Active's MAA for multiple sclerosis drug receives EMA acceptance for review.  // PharmaWatch: CNS;Sep2012, Vol. 11 Issue 9, p10 

    The article reports on the announcement made by Active Biotech regarding the completion by the European Medicines Agency (EMA) of the marketing authorization application (MAA) validation process and acceptance for review of laquinimod for the treatment of relapsing-remitting multiple sclerosis...

  • Multiple Sclerosis.  // PharmaWatch: CNS;November 2003, Vol. 2 Issue 11, p17 

    Reports on developments relating to multiple sclerosis (MS) treatment. Phase II of Active Biotech's multiple sclerosis drug; Positive long-term results for MS patients shown by Serono's Rebif drug; Study showing long-term effect of Biogen's MS drug.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics